Cancer Genetics Prices IPO; Expects $6M in Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics priced its initial public offering at $10 per share today, expecting to raise gross proceeds of $6 million.

Shares of the Rutherford, NJ-based cancer diagnostics company were expected to begin trading today on the OTCQB Marketplace under ticker symbol "CGIX". Cancer Genetics is offering 600,000 shares of its common stock. The $10 price is at the low end of a $10 to $12 range that the company previously said it anticipated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.